The National CFIDS Foundation announced that they will be funding two grants totaling $225,000 to fund new research into CFIDS/ME and its association with a leukemic cell phenotype that it has identified in some patients with the disease. A paper written by Kerr also noted abnormal expressed genes “associated with hematologic disease. You can read Karr’s paper at this link: Gene Expression Subtypes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.
Through bone marrow biopsies and blood samples, researchers say they have a “preliminary indication” that problems exist in the bone marrow of the ME/CFS patients with this problem.
By using the latest in flow cytometry technologies combined with cytogenetic profiles, the NCF has been able to advance its own theories about the disease. This has allowed us to share important data with various top experts worldwide in the leukemia field as well as those engaged in bone marrow research.”
Receiving these research grants are Hany El-Shemy, PhD, Professor of Biochemistry at Cairo University in Egypt. He will be will be evaluating numerous compounds in-vitro against acute myeloid leukemia (AML) cell lines. He likes to use plant-based botanicals to eradicate the acute myeloid leukemia cell lines.
Receiving the other grant is Tsvee Lapidot, PhD, Professor of Immunology at the Weizmann Institute of Science in Israel. His research interests include the mechanisms of stem cell migration and immune development, the regulation of the bone marrow reservoir of immature and maturing luekocytes as part of host defense and repair during homeostasis and alarm situations and the role of stromal cells, cytokines, chemokines, adhesion molecules and proteolytic enzymes in normal and leukemic human hematopoiesis.